Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here